Inhibitory actions of the phosphatidylinositol 3-kinase inhibitor LY294002 on the human Kv1.5 channelPAPER

British Journal of Pharmacology

Volumn 156, Issue 2, 2009, Pages 377-387

  Wu, J ^a,b   Ding, W G ^b   Matsuura, H ^a,b   Tsuji, K ^a   Zang, W J ^a   Horie, M ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Binding site; I Kur; Kv1.5; LY294002; Open channel block; PI3K; Site directed mutagenesis

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ARGININE; ISOLEUCINE; LEUCINE; LY 303511; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POTASSIUM CHANNEL KV1.5; THREONINE; UNCLASSIFIED DRUG; VALINE; WORTMANNIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANDROSTANE DERIVATIVE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE;

AMINO ACID ANALYSIS; ARTICLE; BINDING SITE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; HEART ATRIUM; HEART VENTRICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; MEMBRANE DEPOLARIZATION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; REENTRY ARRHYTHMIA; ANIMAL; CELL MEMBRANE POTENTIAL; CRICETULUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; HAMSTER; MUTATION; SITE DIRECTED MUTAGENESIS; TIME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; BINDING SITES; CHO CELLS; CHROMONES; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; KV1.5 POTASSIUM CHANNEL; MEMBRANE POTENTIALS; MORPHOLINES; MUTAGENESIS, SITE-DIRECTED; MUTATION; PATCH-CLAMP TECHNIQUES; TIME FACTORS;

EID: 67650218657     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00017.x     Document Type: Article

References (46)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl 2 S1 S209.
2. Andér M, Luzhkov VB, Åqvist J (2008). Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state - docking and computer simulations of a homology model. Biophys J 94 : 820 831.
3. Brendel J, Peukert S (2003). Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Curr Med Chem Cardiovasc Hematol Agents 1 : 273 287.
4. Bril A (2002). Recent advances in arrhythmia therapy: treatment and prevention of atrial fibrillation. Curr Opin Pharmacol 2 : 154 159.
5. Caballero R, Moreno I, Gonzalez T, Valenzuela C, Tamargo J, Delpon E (2002). Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). Cardiovasc Res 56 : 104 117.
6. + currents. J Pharmacol Exp Ther 304 : 706 712.
7. Choi BH, Choi JS, Jeong SW, Hahn SJ, Yoon SH, Jo YH et al. (2000). Direct block by bisindolylmaleimide of rat Kv1.5 expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 293 : 634 640.
8. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ (2001). Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 37 : 371 378.
9. Crijns HJ, Van Gelder IC, Walfridsson H, Kulakowski P, Ronaszeki A, Dedek V et al. (2006). Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm 3 : 1321 1331.
10. + channels. J Biol Chem 279 : 394 400.
11. Decher N, Kumar P, Gonzalez T, Renigunta V, Sanguinetti MC (2005). Structural basis for competition between drug binding and Kvβ 1.3 accessory subunit-induced N-type inactivation of Kv1.5 channels Mol Pharmacol 68 : 995 1005.
12. Decher N, Kumar P, Gonzalez T, Pirard B, Sanguinetti MC (2006). Binding site of a novel Kv1.5 blocker: a 'foot in the door' against atrial fibrillation. Mol Pharmacol 70 : 1204 1211.
13. Ding J, Vlahos CJ, Liu R, Brown RF, Badwey JA (1995). Antagonists of phosphatidylinositol 3-kinase block activation of several novel protein kinases in neutrophils. J Biol Chem 270 : 11684 11691.
14. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN (2007). The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 50 : 35 40.
15. Eldstrom J, Choi WS, Steek DF, Fedida D (2003). SAP97 increases Kv1.5 currents through an indirect N-terminal mechanism. FEBS lett 547 : 205 211.
16. Eldstrom J, Wang Z, Xu H, Pourrier M, Ezrin A, Gibson K et al. (2007). The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol Pharmacol 72 : 1522 1534.
17. El-Kholy W, Macdonald PE, Lin JH, Wang J, Fox JM, Light PE et al. (2003). The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism. FASEB J 17 : 720 732.
18. + channel current. Circ Res 73 : 210 216. (Pubitemid 23173072)
19. Feng J, Xu D, Wang Z, Nattel S (1998). Ultrarapid delayed rectifier current inactivation in human atrial myocytes: properties and consequences. Am J Physiol 275 : H1717 H1725.
20. Franqueza L, Valenzuela C, Delpón E, Longobardo M, Caballero R, Tamargo J (1998). Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels. Br J Pharmacol 125 : 969 978.
21. + channels via PI3-kinase, PDK1 and SGK1. Pflugers Arch 443 : 625 634.
22. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391 : 85 100.
23. Herrera D, Mamarbachi A, Simoes M, Parent L, Sauve R, Wang Z et al. (2005). A single residue in the S6 transmembrane domain governs the differential flecainide sensitivity of voltage-gated potassium channels. Mol Pharmacol 68 : 305 316.
24. Knight ZA, Chiang GG, Alaimo PJ, Kenski DM, Ho CB, Coan K et al. (2004). Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem 12 : 4749 4759.
25. Knobloch K, Brendel J, Peukert S, Rosenstein B, Busch AE, Wirth KJ (2002). Electrophysiological and antiarrhythmic effects of the novel I(Kur) channel blockers, S9947 and S20951, on left vs. right pig atrium in vivo in comparison with the I(Kr) blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naunyn Schmiedebergs Arch Pharmacol 366 : 482 487.
26. Knobloch K, Brendel J, Rosenstein B, Bleich M, Busch AE, Wirth KJ (2004). Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs. Med Sci Monit 10 : BR221 228.
27. Kristof AS, Pacheco-Rodriguez G, Schremmer B, Moss J (2005). LY303511 (2-Piperazinyl-8- phenyl-4H-1-benzopyran-4-one) Acts via Phosphatidylinositol 3-Kinase-Independent Pathways to Inhibit Cell Proliferation via Mammalian Target of Rapamycin (mTOR)- and Non-mTOR-Dependent Mechanisms. J Pharmacol Exp Ther 314 : 1134 1143.
28. Kyte J, Doolittle RF (1982). A simple method for displaying the hydropathic character of a protein. J Mol Biol 157 : 105 132.
29. Lerche C, Bruhova I, Lerche H, Steinmeyer K, Wei AD, Strutz-Seebohm N et al. (2007). Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter. Mol Pharmacol 71 : 1503 1511.
30. + current in human ventricular myocytes. Circ Res 78 : 689 696. (Pubitemid 26106881)
31. Nattel S, Yue L, Wang Z (1999). Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity. Cell Physiol Biochem 9 : 217 226.
32. Perchenet L, Clement-Chomienne O (2000). Characterization of mibefradil block of the human heart delayed rectifier hKv1.5. J Pharmacol Exp Ther 295 : 771 778.
33. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C et al. (1994). Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 54 : 2419 2423.
34. Regan CP, Stump GL, Wallace AA, Anderson KD, McIntyre CJ, Liverton NJ et al. (2007). In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate. J Cardiovasc Pharmacol 49 : 236 245.
35. Rezazadeh S, Claydon TW, Fedida D (2006). KN-93 (2-[N-(2-hydroxyethyl)]- N-(4-methoxybenzenesulfonyl)]amino-N-(4-chlorocinnamyl)-N-methylbenzylamine), a calcium/calmodulin-dependent protein kinase II inhibitor, is a direct extracellular blocker of voltage-gated potassium channels. J Pharmacol Exp Ther 317 : 292 299.
36. Snyders DJ, Tamkun MM, Bennett PB (1993). Arapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 101 : 513 543.
37. Snyders DJ, Yeola SW (1995). Determinants of antiarrhythmic drug action. Electrostatic and hydrophobic components of block of the human cardiac hKv1.5 channel. Circ Res 77 : 575 583.
38. Strutz-Seebohm N, Gutcher I, Decher N, Steinmeye K, Lang F, Seebohm G (2007). Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode. Cell Physiol Biochem 20 : 791 800.
39. Trotter BW, Nanda KK, Kett NR, Regan CP, Lynch JJ, Stump GL (2006). Design and synthesis of novel soquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. J Med Chem 49 : 6954 6957.
40. Valenzuela C, Delpón E, Franqueza L, Gay P, Pérez O, Tamargo J et al. (1996). Class III antiarrhythmic effects of zatebradine. Time-, state-, use-, and voltage-dependent block of hKv1.5 channels. Circulation 94 : 562 570.
41. Varro A, Biliczki P, Iost N, Virag L, Hala O, Kovacs P et al. (2004). Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr Med Chem 11 : 1 11.
42. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269 : 5241 5248.
43. Vos MA (2004). Atrial-specific drugs: the way to treat atrial fibrillation? J Cardiovasc Electrophysiol 15 : 1451 1452.
44. + current similar to Kv1.5 cloned channel currents. Circ Res 73 : 1061 1076.
45. Wettwer E, Hala O, Christ T, Heubach JF, Dobrev D, Knaut M et al. (2004). Role of Ikur in controlling action potential shape and contractility in the human atrium. Influence of chronic atrial fibrillation. Circulation 110 : 2299 2306.
46. + channel. Role of S6 in antiarrhythmic drug binding. Circ Res 78 : 1105 1114.